AMARILLO, TX -- (MARKET WIRE) -- May 02, 2007 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today issued the following progress report on its influenza research, on plans for a study in 150 patients with hepatitis C, and on its Phase 2 clinical trials in Behcet's disease and oral warts in HIV positive patients. The Company also provided information on its forthcoming Annual Meeting.
